OncoMyx Announces Presentations at SITC 2021 of New Data Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme Malignancies

< back

PHOENIX, October 19, 2021 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced two poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021, both virtually and in Washington, D.C.

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center. The posters will be available for onsite viewing November 12-14 from 7am to 5pm EST. Even numbered posters will be presented Saturday, November 13. ePosters will be on display on the SITC 2021 virtual meeting platform from 7am EST on Friday, November 12 until the virtual meeting platform is closed on January 9, 2022.

Titles of the presentations are as follows:

  • (742) Multi-armed myxoma virus induces potent anti-tumor responses in vitro and in vivo
  • (744) Multi-armed myxoma virus has therapeutic potential for treatment of multiple myeloma

Full abstracts are available by clicking the links above. Posters for both presentations will be available on OncoMyx’s website on November 12th.

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well tOncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.

About OncoMyx Therapeutics

OncoMyx Therapeutics is advancing oncolytic immunotherapies with the goal of achieving the greatest therapeutic benefit for more cancer patients. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have the potential to be a safe and effective complement to immunotherapies. OncoMyx has assembled the top immuno-oncology team to develop oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response with the goal of better treating a wide range of cancers. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University.

Corporate Contact: Michael G. Wood, Cofounder, COO, and CFO, mw@oncomyx.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com , +1.858.344.8091